{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-22-000124","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.714821+00:00","generated_at":"2026-06-22T01:31:07.443376+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Praxis Q3 2022 net loss $43.9M; cash $123.7M; PRAX-944 top-line results expected 1Q23","bullets":["Net loss $43.9M vs $44.7M YoY; R&D expenses $30.4M down from $33.1M.","Cash and investments $123.7M, down from $275.9M at year-end 2021; runway into 1Q24.","PRAX-944 Phase 2b Essential1 top-line results for essential tremor expected 1Q23; screening to complete mid-Nov 2022.","PRAX-222 EMBRAVE study for SCN2A-DEE to initiate in 4Q22; initial dose cohort results expected 2023.","PRAX-114 Phase 2 Acapella study in MDD not statistically significant; no further development planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-22-000124","json":"https://secwatch.observer/filing/0001689548-22-000124.json","markdown":"https://secwatch.observer/filing/0001689548-22-000124.md","text":"https://secwatch.observer/filing/0001689548-22-000124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000124/0001689548-22-000124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000124/prax-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:31:07.443376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bfbfe0d164251bf8b9d9f2bd5fb0f278e5cd93f4","claim":"Praxis Precision Medicines, Inc. reported financial results for the third quarter of 2022.","evidence_excerpt":"On November 9, 2022, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000124/0001689548-22-000124-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}